Replies to post #9599 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT +3% on solid 4Q14 results/2015 outlook—despite currency headwinds:

http://www.wsj.com/articles/abbott-laboratories-profit-grows-54-1422538479

Guidance for 2015 non-GAAP EPS is $2.10-2.20 (excluding the branded-generics business being sold to MYL) vs $2.28 in 2014 (including the business being sold to MYL).

At current exchange rates, the stronger US dollar compared to 2014 is expected to shave ABT’s 2015 sales by 6% and EPS by 10%. These currency effects are less severe than for many US-based multinationals because ABT makes a lot of its products locally, especially in India and China.

[DewDiligence]

98% of MYL shareholders endorse “spinversion” into a new Netherlands-based company derived from part of ABT:

http://www.sec.gov/Archives/edgar/data/69499/000119312515025838/d859790dex991.htm

As a reminder… ABT will obtain a 22% equity stake in new Mylan as consideration for ABT’s existing branded-generics business in Europe, Japan, Canada, Australia, and New Zealand. ABT is retaining its branded-generics business in India, China, Latin America, Russia, and all other emerging markets.

New Mylan will trade under the same ticker (MYL), but the transaction is expected to be a taxable event for MYL shareholders.

ABT plans to monetize its newly obtained MYL shares within the next year or so.